Pre-Open Stock Movers: Kezar Life Sciences, Inc. (NASDAQ:KZR) 90% HIGHER; reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a...
By Dhirendra Tripathi Investing – Merck (NYSE:MRK) shares rose 1% Thursday ahead of the day’s listing of Organon (NYSE:OGN_w), its spun-off business that has a broad...
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
|Average||26.75 (+392.63% Upside)|
|No. of Analysts||8|